EYEN - צמיחת הכנסות ב-12 חודשים נגררים eyenovia.com

Eyenovia, Inc. (EYEN) is developing innovative microdosing systems for eye drops, targeting high margins following FDA approval. The rolling 12-month sales growth rate compared to the previous year confirms the development vector, where -100.00 determines the current status of the parameter. The business remains independent of economic cycles due to stable demand for glaucoma treatment. The Optejet ecosystem ensures high patient loyalty through the use of specialized cartridges.
eyenovia.com (EYEN) - פילוחי מדדים ודוחות פיננסיים

For Eyenovia, Inc. (EYEN), the year-over-year trend of core revenue over a rolling 12-month period reflects the efficiency of scaling sales while delegating production and clinical trials to external partners. The current value of -100.00 measures the pace of sales expansion across a continuous timeframe, allowing investors to assess the resilience of the outsourcing business model to macroeconomic shocks and avoid capital drawdowns during industry downturns.